Acadia Pharmaceuticals: Q3 2024 Financial Results Preview

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is set to release its third quarter 2024 financial results on November 6, 2024. Investors will be closely watching the company's performance, particularly in light of its recent revenue growth and strategic initiatives. This article provides a preview of what investors can expect from Acadia's Q3 2024 financial results.


Acadia's revenue growth trajectory has been impressive in recent quarters. In the first quarter of 2024, the company reported net product sales of $205.8 million, representing a 74% year-over-year increase. This growth was primarily driven by the addition of DAYBUE, a treatment for Rett syndrome, and the continued growth of NUPLAZID, a treatment for Parkinson's disease psychosis. Investors can expect to see continued growth in net product sales for both NUPLAZID and DAYBUE in the Q3 2024 financial results.


Key drivers behind Acadia's R&D expenses include investments in late-stage trials for Prader-Willi syndrome and Alzheimer's disease psychosis, as well as early-stage pipeline development. In the first quarter of 2024, research and development expenses decreased to $59.7 million, mainly due to the expensing of trofinetide commercial supply build in the first quarter of 2023. Investors should expect R&D expenses to remain relatively stable in Q3 2024, as Acadia continues to invest in its pipeline and clinical trials.

Acadia's SG&A expenses have evolved in line with its revenue growth and international expansion. In the first quarter of 2024, SG&A expenses increased to $108.0 million, primarily driven by the annualization of DAYBUE expenses and foundational investments to commercialize trofinetide outside the U.S. As Acadia continues to expand its global footprint, investors can expect SG&A expenses to remain elevated in Q3 2024.


Acadia's cash and investment balance has grown steadily over the past year, reaching $470.5 million at the end of the first quarter of 2024. This strong financial position allows Acadia to invest in its pipeline, support its early-stage development programs, and pursue business development opportunities. Investors can expect Acadia's cash and investment balance to remain robust in Q3 2024, reflecting the company's financial strength and commitment to growth.

In conclusion, investors can expect Acadia Pharmaceuticals' Q3 2024 financial results to reflect continued revenue growth, stable R&D expenses, and elevated SG&A expenses as the company expands its global footprint. With a strong cash and investment balance, Acadia is well-positioned to support its long-term growth and maintain its competitive edge in the pharmaceutical industry.